NOVARTIS AG

Novartis’ 10% stock plunge after MD trial failure shows how rare‑disease risk can ripple through the healthcare sector, urging investors to watch its R&D pivot.

Novartis faces a DM1 setback as del‑desiran misses its primary endpoint, but its robust neuromuscular strategy, 4.8% CAGR outlook, and value‑based reimbursement plans keep investors optimistic.

Novartis’ phase‑3 Lp(a)-lowering trial fails to cut cardiovascular events, showing the gap between biomarker reduction and real‑world benefit.

Novartis’s Lp(a)HORIZON trial cut Lp(a) levels by ~50% but failed to lower cardiovascular events, raising questions about the clinical value of Lp(a) reduction.

Novartis deepens its portfolio with a new SC partnership and Phase‑III data for Remibrutinib, boosting autoimmune depth and market resilience.

Novartis’ remibrutinib hits phase‑III success in RMS, offering superior relapse control and safety—potentially reshaping the oral DMT market and driving value‑based pricing.

Novartis pauses CAR‑T trials while its remibrutinib Phase III win could reshape the MS market—explore safety, pricing, patent cliffs, and M&A impacts.

Explore Novartis’s next earnings amid volatile ECB policy, EU pricing reforms, and rising competition, revealing key cash‑flow strengths and regulatory risks.

Novartis secures FDA approval of Fabhalta, the first oral complement‑inhibitor for IgA nephropathy, offering a new high‑growth treatment pathway with strong clinical data and patient‑centric delivery.

Novartis’s Fabhalta, a novel complement‑inhibitor, earns FDA approval for primary IgA nephropathy, slowing eGFR decline and reducing albuminuria with a strong safety profile.